Related Experiment Videos
The first febrile seizure--antipyretic instruction plus either phenobarbital or placebo to prevent recurrence
Insights
Phenobarbital significantly reduced recurrent febrile seizures in children compared to placebo. A single daily dose of phenobarbital proved more effective than antipyretic counseling for preventing seizure recurrence after an initial febrile seizure.
Area of Science:
- Pediatrics
- Neurology
- Clinical Pharmacology
Background:
- Febrile seizures are common in children.
- Preventing recurrent febrile seizures is a clinical challenge.
- Current management often relies on parental counseling regarding fever control.
Purpose of the Study:
- To compare the efficacy of single daily dose phenobarbital versus placebo in preventing recurrent seizures after an initial simple febrile seizure.
- To evaluate the effectiveness of phenobarbital in conjunction with antipyretic instruction.
Main Methods:
- A randomized, double-blind study involving 79 children with a first simple febrile seizure.
- Participants received either phenobarbital (5 mg/kg/day) or placebo for 12 months, alongside fever control instructions.
- Compliance was monitored via urine riboflavin fluorescence; serum phenobarbital levels were also assessed.
Main Results:
- Phenobarbital significantly reduced the incidence of recurrent seizures (2/39) compared to placebo (10/40) (P < 0.02).
- Average serum phenobarbital levels were maintained at 1.4 mg/dl throughout the study.
- Compliance monitoring confirmed adherence to the prescribed medication regimen.
Conclusions:
- Single daily dose phenobarbital is more effective than antipyretic counseling alone in preventing recurrent seizures following an initial febrile seizure.
- Phenobarbital represents a viable prophylactic option for children at risk of recurrent febrile convulsions.
- Further research may explore optimal dosing and long-term effects.
Abstract:
A randomized double-blind study was carried out comparing single daily dose phenobarbital plus antipyretic instruction to a placebo plus antipyretic instruction to prevent a recurrent seizure following an initial simple febrile seizure. Parents of 138 consecutive children presenting to an emergency room with a first simple febrile convulsion received verbal and written instructions about fever control. Seventy-nine then agreed to participate in this study. Children were randomized to receive either placebo with riboflavin tracer (n = 40) or phenobarbital 5 mg/kg in a single daily dose with a riboflavin tracer (n = 39) for 12 months or until another seizure occurred. Urine fluorescence for riboflavin was used to monitor compliance in all patients. Serum phenobarbital levels were obtained at each follow-up visit and averaged 1.4 mg/dl throughout the study. The significant difference (P less than 0.02) in the incidence of recurrent seizures between patients receiving phenobarbital (2/39) and those receiving placebo (10/40) suggests that a single daily dose of phenobarbital is more effective than counseling parents about antipyretic therapy in preventing recurrent seizures following an initial febrile seizure.